Categories
Publications & Presentations
Discover the main highlights of our industry in our latest publications.
Access to Care
Discover a complete record of access to care issues by region and PPTA activities in support of access to therapies.
Safety & Quality
Learn more about the regulatory policies and the Association’s voluntary standards for safety & quality standards.
Plasma Collection & Manufacturing
Learn more about plasma collection and discover certified plasma centers near you.
The Source Magazine
Subscribe to the international magazine of the plasma protein therapeutics industry.
Plasma FAQS
Get answers about plasma therapies and the processes surrounding donation and collection procedures.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
Sep 1, 2021
The Source Fall 2021
Magazine of the plasma protein therapeutics industry - Fall 2021
All
The Source Magazine
https://drive.google.com/file/d/18ZMDuw0MnmyjHMdEOtrm6hWU9lt5JRMF/view?usp=sharing
Sep 1, 2021
The Source Fall 2021
Magazine of the plasma protein therapeutics industry - Fall 2021
All
The Source Magazine
https://drive.google.com/file/d/18ZMDuw0MnmyjHMdEOtrm6hWU9lt5JRMF/view?usp=sharing
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
No results found